Neutralizing Antibody Validation Testing and Reporting Harmonization
Evolving immunogenicity assay performance expectations and a lack of harmonized neutralizing antibody validation testing and reporting tools have resulted in significant time spent by health authorities and sponsors on resolving filing queries. A team of experts within the American Association of Pharmaceutical Scientists’ Therapeutic Product Immunogenicity Community across industry and the Food and Drug Administration addressed challenges unique to cell-based and non-cell-based neutralizing antibody assays. Harmonization of validation expectations and data reporting will facilitate filings to health authorities and are described in this manuscript. This team provides validation testing and reporting strategies and tools for the following assessments: (1) format selection; (2) cut point; (3) assay acceptance criteria; (4) control precision; (5) sensitivity including positive control selection and performance tracking; (6) negative control selection; (7) selectivity/specificity including matrix interference, hemolysis, lipemia, bilirubin, concomitant medications, and structurally similar analytes; (8) drug tolerance; (9) target tolerance; (10) sample stability; and (11) assay robustness. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
The AAPS journal - 25(2023), 4 vom: 08. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Myler, Heather [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Anti-drug antibodies (ADA) |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1208/s12248-023-00830-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144374805 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144374805 | ||
| 003 | DE-627 | ||
| 005 | 20240118100405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12248-023-00830-5 |2 doi | |
| 035 | |a (DE-627)OLC2144374805 | ||
| 035 | |a (DE-He213)s12248-023-00830-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 100 | 1 | |a Myler, Heather |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutralizing Antibody Validation Testing and Reporting Harmonization |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Evolving immunogenicity assay performance expectations and a lack of harmonized neutralizing antibody validation testing and reporting tools have resulted in significant time spent by health authorities and sponsors on resolving filing queries. A team of experts within the American Association of Pharmaceutical Scientists’ Therapeutic Product Immunogenicity Community across industry and the Food and Drug Administration addressed challenges unique to cell-based and non-cell-based neutralizing antibody assays. Harmonization of validation expectations and data reporting will facilitate filings to health authorities and are described in this manuscript. This team provides validation testing and reporting strategies and tools for the following assessments: (1) format selection; (2) cut point; (3) assay acceptance criteria; (4) control precision; (5) sensitivity including positive control selection and performance tracking; (6) negative control selection; (7) selectivity/specificity including matrix interference, hemolysis, lipemia, bilirubin, concomitant medications, and structurally similar analytes; (8) drug tolerance; (9) target tolerance; (10) sample stability; and (11) assay robustness. Graphical Abstract | ||
| 650 | 4 | |a anti-drug antibodies (ADA) | |
| 650 | 4 | |a FDA | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a neutralizing antibodies (NAb) | |
| 650 | 4 | |a regulatory guidance | |
| 650 | 4 | |a validation | |
| 700 | 1 | |a Pedras-Vasconcelos, João |4 aut | |
| 700 | 1 | |a Lester, Todd |4 aut | |
| 700 | 1 | |a Civoli, Francesca |4 aut | |
| 700 | 1 | |a Xu, Weifeng |4 aut | |
| 700 | 1 | |a Wu, Bonnie |4 aut | |
| 700 | 1 | |a Vainshtein, Inna |4 aut | |
| 700 | 1 | |a Luo, Linlin |4 aut | |
| 700 | 1 | |a Hassanein, Mohamed |4 aut | |
| 700 | 1 | |a Liu, Susana |4 aut | |
| 700 | 1 | |a Ramaswamy, Swarna Suba |4 aut | |
| 700 | 1 | |a Mora, Johanna |4 aut | |
| 700 | 1 | |a Pennucci, Jason |4 aut | |
| 700 | 1 | |a McCush, Fred |4 aut | |
| 700 | 1 | |a Lavelle, Amy |4 aut | |
| 700 | 1 | |a Jani, Darshana |4 aut | |
| 700 | 1 | |a Ambakhutwala, Angela |4 aut | |
| 700 | 1 | |a Baltrukonis, Daniel |4 aut | |
| 700 | 1 | |a Barker, Breann |4 aut | |
| 700 | 1 | |a Carmean, Rebecca |4 aut | |
| 700 | 1 | |a Chung, Shan |4 aut | |
| 700 | 1 | |a Dai, Sheng |4 aut | |
| 700 | 1 | |a DeWall, Stephen |4 aut | |
| 700 | 1 | |a Dholakiya, Sanjay L. |4 aut | |
| 700 | 1 | |a Dodge, Robert |4 aut | |
| 700 | 1 | |a Finco, Deborah |4 aut | |
| 700 | 1 | |a Yan, Haoheng |4 aut | |
| 700 | 1 | |a Hays, Amanda |4 aut | |
| 700 | 1 | |a Hu, Zheng |4 aut | |
| 700 | 1 | |a Inzano, Cynthia |4 aut | |
| 700 | 1 | |a Kamen, Lynn |4 aut | |
| 700 | 1 | |a Lai, Ching-Ha |4 aut | |
| 700 | 1 | |a Meyer, Erik |4 aut | |
| 700 | 1 | |a Nelson, Robert |4 aut | |
| 700 | 1 | |a Paudel, Amrit |4 aut | |
| 700 | 1 | |a Phillips, Kelli |4 aut | |
| 700 | 1 | |a Poupart, Marie-Eve |4 aut | |
| 700 | 1 | |a Qu, Qiang |4 aut | |
| 700 | 1 | |a Abhari, Mohsen Rajabi |4 aut | |
| 700 | 1 | |a Ryding, Janka |4 aut | |
| 700 | 1 | |a Sheldon, Curtis |4 aut | |
| 700 | 1 | |a Spriggs, Franklin |4 aut | |
| 700 | 1 | |a Warrino, Dominic |4 aut | |
| 700 | 1 | |a Wu, Yuling |4 aut | |
| 700 | 1 | |a Yang, Lin |4 aut | |
| 700 | 1 | |a Pasas-Farmer, Stephanie |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The AAPS journal |d Springer International Publishing, 2004 |g 25(2023), 4 vom: 08. Juli |h Online-Ressource |w (DE-627)474385221 |w (DE-600)2170248-2 |w (DE-576)281264910 |x 1550-7416 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:4 |g day:08 |g month:07 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12248-023-00830-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2474 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 4 |b 08 |c 07 | ||